Total buying$00 buys
ORKA
Oruka Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$4.40M17 sells
Net open-market−$4.40MBuying minus selling
Active insiders4Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 15, 2026
Open-market transaction mix · 17 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 5 | 0 | $0 | $987k | -$987k |
| Oct 2026 | 0 | 12 | 0 | $0 | $3.42M | -$3.42M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- KO-$1.2M
- QT-$858.4k
- AA-$51.0k
ORKA transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | Klein Lawrence OttoCEO | S · sale10b5-1 detectedSEC filing ↗ | -$1.35MView disclosure → | |
ORKAOruka Therapeutics, Inc. | Klein Lawrence OttoCEO | M · exercise10b5-1 detectedSEC filing ↗ | $195kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Agarwal ArjunSVP | S · sale10b5-1 detectedSEC filing ↗ | -$51.0kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | $0View disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | S · sale10b5-1 detectedSEC filing ↗ | -$254kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | S · sale10b5-1 detectedSEC filing ↗ | -$56.7kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | S · sale10b5-1 detectedSEC filing ↗ | -$357kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | S · sale10b5-1 detectedSEC filing ↗ | -$267kView disclosure → | |
ORKAOruka Therapeutics, Inc. | Quinlan Paul TGC | M · exercise10b5-1 detectedSEC filing ↗ | $78.0kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period29transactionstxns
- S · Open-market sells · dominant17 · 59%
- M · Option exercise12 · 41%
Activity by reported role
A joint filing can contribute to multiple rolesCMO9
SVP9
GC6
Chief executive officer5
Reported Holdings After
Separated by insider, security, and ownership type
Agarwal ArjunCommon Stock · Direct
14,219Oct 12, 2026
Goncalves JoanaCommon Stock · Direct
31,771Oct 15, 2026
Quinlan Paul TCommon Stock · Direct
29,995Sep 21, 2026
Klein Lawrence OttoCommon Stock · Direct
923,128Oct 01, 2026
Agarwal ArjunEmployee Stock Option (right to buy) · Direct
56,875Oct 12, 2026
Quinlan Paul TEmployee Warrant (right to buy) · Direct
79,996Sep 21, 2026
Klein Lawrence OttoEmployee Warrant (right to buy) · Direct
1,528,513Oct 01, 2026
Goncalves JoanaEmployee Stock Option (right to buy) · Direct
190,063Oct 15, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Oruka Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Oruka Therapeutics, Inc.?
Goncalves Joana, Agarwal Arjun, Klein Lawrence Otto, Quinlan Paul T.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Goncalves Joana reported a sale on Oct 15, 2026 valued at $15.5k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $4,407,582.08. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.